Episode 3: can we trust science to police itself? – podcast
In our third and final episode, we talk about trust in science. In particular, how historical cases of abuse led many in our groups to questiongene editing, science and medicine. If we focus on the past, will we ever move forward?Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 19, 2020 Category: Science Authors: Presented by Steve Scott and produced by Max Sanderson with Pascal Wyse, Shanida Scotland, Katherine Godfrey, Emilie Glaser, Alok Jha, Charlie Phillips and Lindsay Poulton Tags: Gene editing Science Biology Genetics Health Sickle cell disease Society Source Type: news

WSSU partners with Triad health system to treat, protect student athletes
One of the Triad ’s largest health systems is partnering with Winston-Salem State University to provide sports medicine and orthopedic services to student athletes.  The WSSU football and men’s and women’s basketball programs will benefit from the university’s partnership with Wake Forest Baptist Health, n ot only by having physicians on the sidelines at games, but through injury prevention and health screenings as well. Concussion management, physicals, sickle cell screenings, behavioral… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 18, 2020 Category: Pharmaceuticals Authors: John Joyce Source Type: news

10 African Americans Who Have Shaped  Public Health
By Casey Bishopp, Communications officer, IntraHealth International ; Sabra Farquharson, Business development officer, IntraHealth InternationalFebruary 18, 2020We’re celebrating the legacies of ten African Americans in public health this month—shining a light on the invaluable contributions made by these scholars and health workers. According to themost recent report form the Health Resources and Services Administration, African Americans make up 11.6% of the US health workforce, and throughout American history have made invaluable contributions to greater public health in fields s...
Source: IntraHealth International - February 17, 2020 Category: International Medicine & Public Health Authors: cbishopp Source Type: news

Sickle Cell Disease: After Years Of Neglect Some Promise For Sufferers
In the past five years there has very encouraging news on the sickle cell disease drug development front. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, there are now a number of promising new therapies on the market. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 17, 2020 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Source Type: news

Sierra Leone: Nigerian Expert Engages Media On Sickle Cell
[Concord] Nigerian Professor of Genetics and Animal breeding, Professor Cyril Oroname Otoikhian, last Friday, 24th January, held a public lecture with Sierra Leonean journalists on his intention to eradicate sickle cell in Africa. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 29, 2020 Category: African Health Source Type: news

Engineered capillaries model traffic in tiny blood vessels
(University of Washington Health Sciences/UW Medicine) 3D microvessels have been created to observe how red blood cells transit ultra-small blood vessels. They squeeze single-file through microvessels to bring oxygen and nutrients. Red cells burdened with malaria stall, blocking the blood vessel. The platform is expected to have other uses in studies of how microvascular damage occurs in diabetes and sickle cell anemia. They might be further developed to supply blood circulation to organ repair patches or to 3D printed transplants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 23, 2020 Category: International Medicine & Public Health Source Type: news

2019's new medicines
(American Chemical Society) With 48 drugs approved by the US Food and Drug Administration (FDA), 2019 was another highly productive year for the pharmaceutical industry. The new medicines include treatments for various cancers, sickle cell disease, migraines and postpartum depression. However, the steady flow of drugs could be masking troubling signs about the health of the industry, according to Chemical& Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2020 Category: International Medicine & Public Health Source Type: news

Sierra Leone: Nigerian Prof. to Deliver Free Lectures And Test On Sickle Cell
[Concord] A Nigerian Genetics, Professor Cyril Oroname Otoikhian, who is leading a fight to end sickle cell genetic in Africa, has collaborated with Prince Harrison Ehimiyen Foundation in Nigeria and Concord Times Communications to take the fight to Sierra Leone. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 20, 2020 Category: African Health Source Type: news

While promoting diseases like cancer, these enzymes also cannibalize each other
(Georgia Institute of Technology) In diseases like cancer, atherosclerosis, and sickle cell anemia, cathepsins promote their propagation. Drug trials to inhibit these enzymes have failed due to baffling side effects. Now a new study examines cathepsins in systems to remove some of the bafflement. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 20, 2020 Category: Cancer & Oncology Source Type: news

At 16, She ’s a Pioneer in the Fight to Cure Sickle Cell Disease
Helen Obando is the youngest person ever to get a gene therapy that scientists hope will cure the disease, which afflicts 100,000 Americans. (Source: NYT Health)
Source: NYT Health - January 12, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Sickle Cell Anemia Genetics and Heredity Genetic Engineering Stem Cells Clinical Trials Boston Children ' s Hospital Bluebird Bio Source Type: news

A Teenager ’s Breakthrough Gene Therapy for Sickle Cell Disease
Doctors reset Helen Obando ’s DNA in an effort to cure her of a painful genetic blood disorder. She’s the youngest person to receive the treatment. (Source: NYT Health)
Source: NYT Health - January 10, 2020 Category: Consumer Health News Tags: Sickle Cell Anemia DNA (Deoxyribonucleic Acid) Genetics and Heredity Boston Children ' s Hospital Clinical Trials FX (TV Network) Hulu.com The Weekly (TV Program) Source Type: news

Sickle Cell Disease (Anemia)
Title: Sickle Cell Disease (Anemia)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/10/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - January 10, 2020 Category: Anesthesiology Source Type: news

Nigeria: We Lost 80 Members Over Blood Shortage, Says Kano Sickle Cell Association
[Vanguard] Mr Abdulkadir Muhammad, the Secretary, Kano Sickle Cell Club, says no fewer than 80 of their members died in 2019 as a result of shortage of blood caused by economic hardship. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 9, 2020 Category: African Health Source Type: news

Aruvant Receives FDA Rare Pediatric Disease Designation for ARU-1801 for the Treatment of Sickle Cell Disease
ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and ß-thalassemia ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for... Biopharmaceuticals, FDA Aruvant Sciences, sickle cell, thalassemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 8, 2020 Category: Pharmaceuticals Source Type: news

Effort To Control Opioids In An ER Leaves Some Sickle Cell Patients In Pain
(Source: NPR Health and Science)
Source: NPR Health and Science - January 2, 2020 Category: Consumer Health News Authors: Sam Whitehead Source Type: news

Novartis wins Medicaid approval for new sickle cell drug in key U.S. states
Novartis AG has secured Medicaid coverage for a pricey new sickle cell disease therapy in two U.S. states just weeks after winning U.S. approval, following an early campaign to convince local officials of its value, according to a company executive and a Reuters review of public filings. The approvals from the Florida and Alabama Medicaid health programs for the poor and disabled mark exceptionally fast acceptance for the treatment, which can cost up to $113,000 an (Source: Reuters: Health)
Source: Reuters: Health - December 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Fresh off first sickle cell drug approval, Global Blood strikes new deals
In the wake of its FDA nod, the South City company has lined up a $150 million loan agreement and, separately, a potential $375 million partnership with Syros Pharmaceuticals. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 19, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

eyeforpharma Awards: Recognizing and celebrating innovation
At the eyeforpharma Awards we strive to reward, support and incentivise innovation, especially when it comes to the value pharma offers patients and customers. We only recognize meaningful innovation which takes our industry, our reputation and our impact forward and the entries are measured objectively by external judges.  I was amazed by the quality of entries this year. With 500 nominations, our judges – a mixture of patients and health professionals – deliberated hard for many hours, finally settling on just 16 winners, each exemplifying the very best work in pharma.   By ‘best’...
Source: EyeForPharma - December 19, 2019 Category: Pharmaceuticals Authors: Paul Simms Source Type: news

Stem-Cell Transplant Improves Outcomes of High-Risk Sickle-Cell Disease Stem-Cell Transplant Improves Outcomes of High-Risk Sickle-Cell Disease
Familial haploidentical stem-cell transplant improves outcomes in children and adolescents with high-risk sickle-cell disease, researchers report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Oral Arginine as Adjuvant for Vaso-Occlusive Crisis Management Oral Arginine as Adjuvant for Vaso-Occlusive Crisis Management
Oral arginine supplementation significantly increased plasma arginine levels and improved acute pain-related outcomes in children with sickle cell disease in a randomized, placebo-controlled, phase 2 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2019 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Gene Therapy May Aid In Sickle Cell Disease Treatment
Scientists report progress using gene therapy to treat sickle cell disease, a common and devastating genetic blood disorder. (Source: NPR Health and Science)
Source: NPR Health and Science - December 10, 2019 Category: Consumer Health News Authors: Rob Stein Source Type: news

Two New Drugs Help Relieve Sickle-Cell Disease. But Who Will Pay?
Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life. (Source: NYT Health)
Source: NYT Health - December 7, 2019 Category: Consumer Health News Authors: Gina Kolata Tags: Drugs (Pharmaceuticals) Health Insurance and Managed Care Sickle Cell Anemia Prices (Fares, Fees and Rates) Stroke Clinical Trials Hemoglobin Food and Drug Administration Novartis AG Global Blood Therapeutics Source Type: news

New tool for rapidly analyzing CRISPR edits reveals frequent production of unintended edits
(Burness) Amidst rising hopes for using CRISPR gene editing tools to repair deadly mutations linked to conditions like cystic fibrosis and sickle cell disease, a new study in the Nature journal Communications Biology describes a new innovation that could accelerate this work by rapidly revealing unintended and potentially harmful changes introduced by a gene editing process. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 6, 2019 Category: Biology Source Type: news

Novel Sickle Cell Disease Causes Radical Results In End Of Life Patients
According to Bronte-Hall, the drug allows for greater oxygen delivery and an indirect increase in the hemoglobin. As a result, patients not only reported increased energy but also signs of increased blood flow such as increased color in the face and physical warmth upon touch. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 30, 2019 Category: Pharmaceuticals Authors: Dana Dovey, Contributor Source Type: news

Novel Sickle Cell Drug Causes Radical Results In End Of Life Patients
According to Bronte-Hall, the drug allows for greater oxygen delivery and an indirect increase in the hemoglobin. As a result, patients not only reported increased energy but also signs of increased blood flow such as increased color in the face and physical warmth upon touch. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 30, 2019 Category: Pharmaceuticals Authors: Dana Dovey, Contributor Source Type: news

Monthly News Roundup - November 2019
Oxbryta Granted Early Approval to Target Root Cause of Sickle Cell Disease Roughly 100,000 people in the US have sickle cell disease (SCD), a painful genetic blood disorder that causes sickle-shaped red blood cells. Oxygen delivery to organ systems... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 29, 2019 Category: Pharmaceuticals Source Type: news

Patients and Their Families Give Thanks for Blood Donors
This Thanksgiving, we’re grateful for everyone who has donated lifesaving blood or platelets to help patients in need. Here are a few patients and their families who want to say ... The post... {This is a content summary only. Click the blog post title to continue reading this post, share your comments, browse the blog and more!} (Source: Red Cross Chat)
Source: Red Cross Chat - November 27, 2019 Category: International Medicine & Public Health Authors: American Red Cross Tags: Blood Amazon.com Gift Card appointment blood donation blood donor platelets schedule sickle cell disease thanksgiving Source Type: news

FDA Approves Oxbryta for Treatment of Sickle Cell Disease
Title: FDA Approves Oxbryta for Treatment of Sickle Cell DiseaseCategory: Health NewsCreated: 11/27/2019 12:00:00 AMLast Editorial Review: 11/27/2019 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - November 27, 2019 Category: Anesthesiology Source Type: news

FDA Approves Oxbryta for Treatment of Sickle Cell Disease
TUESDAY, Nov. 26, 2019 -- Oxbryta (voxelotor) has been granted accelerated approval for the treatment of sickle cell disease in patients ages 12 years and older, the U.S. Food and Drug Administration announced Monday. Oxbryta is the first approved... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 26, 2019 Category: General Medicine Source Type: news

Global Blood Therapeutics wins first FDA approval with sickle cell disease med
The drugmaker says its drug, Oxbryta, can be used in combination with Novartis ’s drug, Adakveo, which nabbed FDA approval just last week (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 26, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Global Blood Therapeutics sickle cell disease drug
The U.S. Food and Drug Administration said on Monday it approved a drug from Global Blood Therapeutics Inc to treat sickle cell disease in adults and children 12 years or older. (Source: Reuters: Health)
Source: Reuters: Health - November 26, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA OKs Voxelotor for Root Cause of Sickle Cell Disease FDA OKs Voxelotor for Root Cause of Sickle Cell Disease
Voxelotor targets the root cause of sickle cell disease and was granted accelerated approval to treat adults and children aged 12 years and older.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 26, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves novel treatment to target abnormality in sickle cell disease
Today, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. "Today's approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who live with this debilitating blood disorder," said Acting FDA Commissioner Adm. Brett P. Giroir, M.D. (Source: World Pharma News)
Source: World Pharma News - November 25, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease
November 25, 2019 -- Today, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.“Today’s... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 25, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves voxelotor for sickle cell disease
Oncology News burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 25, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves novel treatment to target abnormality in sickle cell disease
FDA granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 25, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Time to Rethink Ideas About Exercise, Sickle Cell Disease?
Title: Time to Rethink Ideas About Exercise, Sickle Cell Disease?Category: Health NewsCreated: 11/19/2019 12:00:00 AMLast Editorial Review: 11/20/2019 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - November 20, 2019 Category: Anesthesiology Source Type: news

CRISPR For Sickle Cell Disease Shows Promise In Early Test
Scientists are reporting the first evidence that genetically edited cells could be safely helping a patient with sickle cell disease. The cells are producing a crucial oxygen-carrying protein. (Source: NPR Health and Science)
Source: NPR Health and Science - November 19, 2019 Category: Consumer Health News Authors: Rob Stein Source Type: news

Endurance Exercise May Offer Vascular Benefit in Sickle Cell Disease
TUESDAY, Nov. 19, 2019 -- Endurance exercise training may improve skeletal muscle microvasculature in patients with sickle cell disease (SCD), according to a study published online Nov. 19 in Blood. Ang èle N. Merlet, Ph.D., from the Universitè de... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2019 Category: Pharmaceuticals Source Type: news

Early Results Are Positive from Experimental CRISPR Therapies
Two clinical trial participants--one with beta-thalassemia and one with sickle cell disease--appeared to benefit from the gene-editing treatments with minimal side effects, according to the companies. (Source: The Scientist)
Source: The Scientist - November 19, 2019 Category: Science Tags: News & Opinion Source Type: news

Time to Rethink Ideas About Exercise, Sickle Cell Disease?
TUESDAY, Nov. 19, 2019 -- Mild exercise is safe and beneficial for people with sickle cell disease, contrary to traditional beliefs, a new study finds. Sickle cell disease affects blood flow in the body. Because strenuous exercise boosts blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 19, 2019 Category: General Medicine Source Type: news

New Sickle Cell Disease Drug Approved by FDA
Title: New Sickle Cell Disease Drug Approved by FDACategory: Health NewsCreated: 11/18/2019 12:00:00 AMLast Editorial Review: 11/19/2019 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - November 19, 2019 Category: Anesthesiology Source Type: news

Novartis gets FDA ok for sickle-cell drug
Novartis announced it won U.S. FDA approval for its experimental sickle cell disease drug, Adakveo. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 17, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Crizanlizumab: Here Is A New Drug For Sickle Cell Disease
Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2019 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

FDA Approves Crizanlizumab, A New Drug For Sickle Cell Disease
Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2019 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

FDA OKs Crizanlizumab, Targeted Therapy for Sickle Cell Crisis FDA OKs Crizanlizumab, Targeted Therapy for Sickle Cell Crisis
Crizanlizumab binds to P-selectin, a cell adhesion protein that plays a central role in the multicellular interactions that can lead to vaso-occlusion in sickle cell disease.FDA Approvals (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - November 16, 2019 Category: Pediatrics Tags: Hematology-Oncology News Alert Source Type: news

US approves new drug to manage sickle cell disease
U.S. regulators have approved a new medicine that can help manage extremely painful sickle cell disease flare-ups (Source: ABC News: Health)
Source: ABC News: Health - November 15, 2019 Category: Consumer Health News Tags: Health Source Type: news

FDA Approves Adakveo (crizanlizumab-tmca) to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell Disease
Basel, November 15, 2019– Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo (crizanlizumab), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 15, 2019 Category: Drugs & Pharmacology Source Type: news

Novartis sickle-cell drug gets U.S. FDA approval
Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance. (Source: Reuters: Health)
Source: Reuters: Health - November 15, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves crizanlizumab-tmca for sickle cell disease
Oncology Newsburst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 15, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news